Categories

All News India Business Stock market Politics Sports Technology Startups Entertainment Hatke International Automobile Science Travel Miscellaneous
Source: Your story

ElasticRun’s playbook for last-mile delivery; Making job applications faster, smarter

Startups

AI executives maintain strong demand despite cost concerns, while tech giants' carbon emissions rise due to data centers. A "super" El Niño threatens global food prices. In logistics, ElasticRun scales last-mile delivery across India, and Tsenta uses AI to streamline job applications. Other news includes a UK crackdown on unlicensed casino sponsorships, upcoming corporate earnings, and the 2026 FIFA World Cup final halftime show lineup.

Read Full Story
Next Story
Source: Tech Crunch

TechCrunch Mobility: A robotaxi ultimatum

Startups

Uber and Waymo ended their robotaxi partnership in Phoenix, while the NHTSA warned autonomous vehicle developers against interfering with first responders. Proposed federal safety standard changes may benefit Tesla and Zoox. Meanwhile, Rivian raised $1.32 billion in new capital to support production. Other industry news includes a massive AssuranceAmerica data breach, Lyft's acquisition of Serveo's Spanish bike-share business, and Manna Aero's expansion into the United States.

Read Full Story
Next Story
Source: Your story

India's MSMEs power the economy, but most still aren't using AI

Startups

Fynd's Ragini Varma explains how AI can help India's MSMEs automate retail operations, improve efficiency, and grow without adding staff.

Read Full Story
Next Story
Source: Tech Crunch

Reed Jobs would rather talk about curing cancer than his last name

Startups

Reed Jobs' Yosemite, an oncology-focused venture firm launched in 2023, builds biotech companies from early academic research using philanthropy and investment. Targeting $350 million for its second fund, Yosemite aims to create new areas of medicine, including epigenetic gene editing. Jobs notes AI's accelerating impact on drug discovery and clinical trials, expanding opportunities. The firm is actively pursuing challenging "undruggable" targets like p53, a critical tumor suppressor gene.

Read Full Story
Next Story